Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

Flooding-related supply disruption is expected to reduce fourth-quarter revenue by approximately $15 million to $20 million.

Rhea-AI Summary

Integra LifeSciences (IART) lowered its full-year 2026 revenue and adjusted earnings guidance as flooding disrupted production at its Cincinnati facility.

Preliminary, unaudited third-quarter revenue is expected at approximately $410 million to $412 million, with adjusted earnings per diluted share of $0.55 to $0.59. Integra estimates flooding reduced third-quarter revenue by approximately $7 million and expects a fourth-quarter impact of approximately $15 million to $20 million.

Full-year revenue guidance fell from $1.654 billion–$1.695 billion to $1.634 billion–$1.654 billion; adjusted earnings per diluted share guidance fell from $2.40–$2.50 to $2.30–$2.40. Integra expects operating cash flow greater than $85 million in the third quarter and approximately $190 million to $200 million for the year, with full manufacturing operations returning in the second quarter of 2027.

4 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.Operating cash flow expected at greater than $85 million for the third quarter of 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 operating cash flow expected at approximately $190 million to $200 million.
• Minor point. Forward-looking: it has not happened yet and may not happen.Insurance recoveries expected to mitigate a substantial portion of disruption-related earnings impact throughout recovery.
• Minor pointAlternate supply sources activated for certain products, alongside inventory use and Cincinnati restoration activities.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 revenue outlook lowered to $1.634 billion–$1.654 billion from $1.654 billion–$1.695 billion.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Flooding-related supply disruption expected to reduce fourth-quarter revenue by approximately $15 million to $20 million. 1.2% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cincinnati flooding damaged facility portions, equipment, inventory and other assets; full manufacturing return expected in second-quarter 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 adjusted diluted EPS guidance lowered to $2.30–$2.40 from $2.40–$2.50.
• Minor pointFlooding-related supply disruption estimated to have reduced third-quarter revenue by approximately $7 million.
• Minor pointPreliminary third-quarter results are unaudited and subject to completion of financial closing procedures.

News Explained

Integra expects insurance recoveries to mitigate a substantial portion of the flooding-related earnings impact, but the recovery amount is not yet established: the company is working with its insurer to assess and document property-damage and business-interruption claims.

Argus 15 min delay 5 alerts

-7.15% vs previous close $14.94 last price 13.5x rel. volume Open Argus

Details

Market Reaction – IART

-5.2% Trough in 5 min

$13.03 – $16.11 Day Range

$1.16B Market Cap

On Oct 2, the day this news came out, the latest delayed price for IART is 7.15% below the previous close. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $14.94. Relative volume is exceptionally heavy at 13.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Q3 revenue: $410 million to $412 million Q3 adjusted EPS: $0.55 to $0.59 Q3 revenue impact: Approximately $7 million +5 more

Q3 revenue

$410 million to $412 million

Preliminary third quarter 2026 results; unaudited

Q3 adjusted EPS

$0.55 to $0.59

Preliminary third quarter 2026 results; per diluted share

Q3 revenue impact

Approximately $7 million

Estimated impact of Cincinnati flooding-related supply disruption

Q4 revenue impact

Approximately $15 million to $20 million

Expected impact of Cincinnati flooding-related supply disruption

FY2026 revenue guidance

$1.634 billion to $1.654 billion

Updated from $1.654 billion to $1.695 billion

FY2026 adjusted EPS guidance

$2.30 to $2.40

Per diluted share; updated from $2.40 to $2.50

FY2026 operating cash flow

Approximately $190 million to $200 million

Full-year expectation

Return to full manufacturing operations

During the second quarter of 2027

Expected timing for the Cincinnati facility

Historical Context

1 past event · Latest: Jul 29

1 event

1. Jul 29

   Q2 earnings

   24h Move

   -16.6%

   Q2 results slightly reduced reported revenue outlook while reaffirming adjusted EPS guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”

Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”

Update on Cincinnati Facility

As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed on the second quarter earnings call, flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site. The facility manufactures and supports several products within the Company's Specialty Surgical Technologies portfolio.

Since the event, Integra has continued to execute its business continuity and recovery plans. The Company has utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility. These actions are intended to support customers and mitigate disruption while recovery efforts continue.

Based on its current assessment, Integra estimates that the flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million. The Company expects a return to full manufacturing operations at the site during the second quarter of 2027.

Integra maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the Company expects insurance recoveries to mitigate a substantial portion of the earnings impact associated with the disruption throughout the recovery period and until the facility returns to full manufacturing capacity. The Company continues to work with its insurance carrier to assess and document recoverable losses associated with the event, including both property damage and business interruption claims.

Preliminary Third Quarter Results and Updated Full-Year Guidance

For the third quarter of 2026, the Company expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results as set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures.

For the full year 2026, the Company is updating its reported revenue outlook from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion. The Company is updating its adjusted earnings per diluted share guidance from a range of $2.40 to $2.50 to a range of $2.30 to $2.40 and expects operating cash flow for the year to be approximately $190 million to $200 million.

The third quarter preliminary results and updated full-year guidance reflect revised assumptions regarding the expected impact of the July flooding event at the Cincinnati facility, as well as updated assumptions for the broader business for the remainder of the year.

The Company will report its third quarter 2026 financial results during a conference call in October 2026. A press release with the date, time and webcast information will be provided closer to the reporting date. The Company will provide additional information regarding its third quarter financial results and outlook for full-year 2026 at that time.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Integra LifeSciences' updated full-year 2026 guidance?

Integra expects full-year 2026 revenue of $1.634 billion to $1.654 billion and adjusted earnings per diluted share of $2.30 to $2.40. The previous ranges were $1.654 billion to $1.695 billion and $2.40 to $2.50, respectively.

When does Integra LifeSciences expect Cincinnati manufacturing to recover?

Integra expects a return to full manufacturing operations during the second quarter of 2027. July 2026 flooding damaged portions of the Cincinnati facility and disrupted operations.

Does Integra LifeSciences have insurance for the Cincinnati flooding disruption?

Integra maintains property and business interruption insurance covering the Cincinnati facility. The company expects recoveries to mitigate a substantial portion of the disruption-related earnings impact throughout recovery until full manufacturing capacity returns. It continues working with its insurer to assess and document recoverable property damage and business interruption losses.